Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes

Lixisenatide attenuates advanced glycation end products (AGEs)-induced degradation of extracellular matrix in human primary chondrocytes

Osteoarthritis (OA) poses a growing threat to the health of the global population. Accumulation of advanced glycation end-products (AGEs) has been shown to upregulate expression of degradative enzymes such as matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Xin Li, Fangteng Jia, Zhengqing Zhu, Lanfeng Huang
Format: Artikel
Sprache:Englisch
Veröffentlicht: Taylor & Francis Group 2019-12-01
Schriftenreihe:Artificial Cells, Nanomedicine, and Biotechnology
Schlagworte:
Lixisenatide
osteoarthritis
type II collagen
aggrecan
metalloproteinases (MMPs)
a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)
Online-Zugang:https://www.tandfonline.com/doi/10.1080/21691401.2019.1593996
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge